Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Zayd Eldadah

Clinical Cardiac Electrophysiology Washington, DC Medical Doctor

NPI 1184679920 CMS profile 189210

110 Irving St Nw, Suite 2A38, Washington, DC 20010

Open in the dashboard

General payments

$358,468

537 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$737,962 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Zayd Eldadah of Washington, DC is reported in the CMS Open Payments database as having received $358,468 across 537 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $737,962 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,959 57
2024 General $85,666 92
2023 General $103,482 121
2022 General $109,241 122
2021 General $10,037 37
2020 General $13,199 32
2019 General $22,884 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zayd Eldadah
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Zayd Eldadah were reported at $13,959. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Zayd Eldadah Clinical Cardiac Electrophysiology median Middle half National median
2019 $22,884 $2,361 $585–$8,260 $163
2020 $13,199 $993 $247–$4,351 $114
2021 $10,037 $1,185 $326–$4,739 $132
2022 $109,241 $2,073 $554–$6,789 $149
2023 $103,482 $2,568 $759–$8,159 $160
2024 $85,666 $2,557 $703–$7,403 $164
2025 $13,959 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Atricure, Inc. $261,642 229 payments
  2. Abbott Laboratories $59,995 99 payments
  3. Biotronik Inc. $13,948 31 payments
  4. Boston Scientific Corporation $8,427 48 payments
  5. Cardiva Medical, Inc. $6,036 19 payments
  6. Medtronic Vascular, Inc. $2,575 29 payments
  7. Biosense Webster, Inc. $1,643 28 payments
  8. AltaThera Pharmaceuticals LLC $1,000 1 payment
  9. Sanofi-Aventis U.S. LLC $569 2 payments
  10. Medtronic, Inc. $565 13 payments
  11. Other $2,068 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $275,050 88 payments
  2. Travel and Lodging $51,870 112 payments
  3. Food and Beverage $16,482 323 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $7,500 5 payments
  5. Honoraria $3,375 3 payments
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,000 1 payment
  7. Compensation for serving as faculty or as a speaker for a medical education program $1,000 1 payment
  8. Education $141 3 payments
  9. Grant $50 1 payment
Products named General payments · program years 2019–2025
  1. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $238,902 200 payments
  2. ACCENT $41,355 13 payments
  3. ATRICLIP LAA EXCLUSION SYSTEM $40,966 45 payments
  4. SYNERGY ABLATION SYSTEM $21,114 24 payments
  5. ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2) $15,157 10 payments
  6. Ensite Cardiac Mapping System $6,696 4 payments
  7. Accent Pacemaker $4,400 1 payment
  8. Cardiva VASCADE MVP VVCS 6-12F $3,471 11 payments
  9. WATCHMAN $3,023 2 payments
  10. Vascular Closure Device $2,489 4 payments
  11. Other $20,403 233 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

19

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$28,848

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

100%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 19 $28,848

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$154,319

Medicare's payments for the services billed

Medicare patients

441

Average age 77

Services billed

1,568

212 women, 229 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Arthritis 50%
Ischemic heart disease 41%
Heart failure 34%
Chronic kidney disease 28%
Diabetes 27%
Cancer 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $75
$75 — —
Repatha
  • Amgen Inc. $18
$18 — —
RYBELSUS
  • Novo Nordisk Inc $12
$12 — —
Ozempic
  • Novo Nordisk Inc $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

537 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record